PMV Pharmaceuticals, Inc.
PMVP
$0.8522
-$0.0118-1.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.02% | -15.39% | -9.75% | -7.29% | -3.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.79% | -4.72% | -7.17% | -4.64% | 4.01% |
| Operating Income | -5.79% | 4.72% | 7.17% | 4.64% | -4.01% |
| Income Before Tax | -8.48% | 6.86% | 12.26% | 12.06% | 5.96% |
| Income Tax Expenses | -536,733.33% | -402,600.00% | -323,380.00% | 127.27% | 133.33% |
| Earnings from Continuing Operations | 14.87% | 29.06% | 34.07% | 12.04% | 5.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.87% | 29.06% | 34.07% | 12.04% | 5.94% |
| EBIT | -5.79% | 4.72% | 7.17% | 4.64% | -4.01% |
| EBITDA | -6.03% | 5.38% | 8.17% | 5.97% | -2.80% |
| EPS Basic | 21.28% | 35.95% | 40.40% | 18.34% | 10.17% |
| Normalized Basic EPS | 0.52% | 16.75% | 21.84% | 19.17% | 10.20% |
| EPS Diluted | 21.28% | 35.95% | 40.40% | 18.34% | 10.17% |
| Normalized Diluted EPS | 0.52% | 16.75% | 21.84% | 19.17% | 10.20% |
| Average Basic Shares Outstanding | 7.44% | 10.49% | 11.18% | 8.22% | 5.29% |
| Average Diluted Shares Outstanding | 7.44% | 10.49% | 11.18% | 8.22% | 5.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |